H.C. Wainwright analyst Andres Y. Maldonado has maintained their bullish stance on IMAB stock, giving a Buy rating today.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Andres Y. Maldonado has given his Buy rating due to a combination of factors that highlight the potential of I-MAB’s innovative therapies. The company’s recent KOL event underscored the promising clinical data for givastomig, a bispecific antibody targeting Claudin 18.2/4-1BB, which is being developed for advanced gastric and gastroesophageal cancers. The data presented at the event demonstrated strong early efficacy and safety signals when givastomig is combined with nivolumab and chemotherapy, positioning it as a differentiated therapy in the competitive landscape of frontline gastric cancer.
Moreover, givastomig’s ability to cover a broad patient population due to its permissive expression threshold and its mechanism of action that minimizes off-target effects were highlighted as key advantages. The dose-escalation study results showed a high objective response rate and manageable safety profile, further supporting its potential as a best-in-class treatment. These factors, combined with the ongoing expansion of the patient cohort and the anticipation of confirmatory data, contribute to Maldonado’s optimistic outlook on I-MAB’s stock.
In another report released today, Needham also maintained a Buy rating on the stock with a $5.00 price target.